ALG.APV-527 is under clinical development by Alligator Bioscience and currently in Phase II for Malignant Pleural Mesothelioma. According to GlobalData, Phase II drugs for Malignant Pleural Mesothelioma have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALG.APV-527’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALG.APV-527 overview
ALG.APV-527 is under development for the treatment of metastatic solid tumors such as colon carcinoma, melanoma, breast cancer, cervical cancer, non-small cell-lung cancer, prostate cancer, endometrial cancer, renal cancer, gastric cancer, colorectal cancer, malignant mesothelioma, malignant pleural mesothelioma, urothelial carcinoma, head and neck cancer, pancreatic cancer, ovarian cancer, throat cancer and gastroesophageal (GE) junction carcinomas. It is based on SLIMCAN concept. The drug candidate is a bi-specific antibody that acts by targeting 4-1BB (CD137), a member of tumor necrosis factor receptor superfamily (TNFRSF) and 5T4 protein. It is developed using ALLIGATOR-GOLD and FIND (Fragment Induced Diversity) technology. It is administered through intravenous route.
Alligator Bioscience overview
Alligator Bioscience develops antibody-based pharmaceuticals for cancer treatment. Its preclinical development phase products ATOR-1017 and ALG.APV-527 are antibodies for activating the co-stimulatory receptor 4-1BB and for treating tumor-directed immunotherapy respectively. The company develops immunotherapies such as agonistic mono- and bispecific antibodies. It develops immunotherapeutic product candidates using proprietary technologies, Alligator-Gold and fragment induced diversity (FIND). Alligator Bioscience is headquartered in Lund, Sweden.
For a complete picture of ALG.APV-527’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
